<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Heiman, M.L.</title>
    <link>http://repub.eur.nl/res/aut/15294/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13417/</link>
      <pubDate>2004-06-01T00:00:00Z</pubDate>
      <description>Ghrelin is a peptide predominantly produced by the stomach. Ghrelin
      displays strong GH-releasing activity. This activity is mediated by the
      activation of the so-called GH secretagogue receptor type 1a. This
      receptor had been shown to be specific for a family of synthetic, peptidyl
      and nonpeptidyl GH secretagogues. Apart from a potent GH-releasing action,
      ghrelin has other activities including stimulation of lactotroph and
      corticotroph function, influence on the pituitary gonadal axis,
      stimulation of appetite, control of energy balance, influence on sleep and
      behavior, control of gastric motility and acid secretion, and influence on
      pancreatic exocrine and endocrine function as well as on glucose
      metabolism. Cardiovascular actions and modulation of proliferation of
      neoplastic cells, as well as of the immune system, are other actions of
      ghrelin. Therefore, we consider ghrelin a gastrointestinal peptide
      contributing to the regulation of diverse functions of the gut-brain axis.
      So, there is indeed a possibility that ghrelin analogs, acting as either
      agonists or antagonists, might have clinical impact.</description>
    </item>
  </channel>
</rss>